APNHF Stock Chart & Stats
$8.00
$0.25(2.04%)
At close: 4:00 PM EDT
$8.00
$0.25(2.04%)
Day’s Range― - ―
52-Week Range$5.10 - $10.18
Previous CloseN/A
Volume100.00
Average Volume (3M)3.00
Market Cap
$4.32B
Enterprise Value$4.66B
Total Cash (Recent Filing)$12.34B
Total Debt (Recent Filing)$36.46B
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.52%
Share Statistics
EPS (TTM)7.44
Shares Outstanding446,252,320
10 Day Avg. Volume10
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue0.10
Enterprise Value/Gross Profit0.24
Enterprise Value/Ebitda0.42
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aspen Pharmacare Holdings News
APNHF FAQ
What was Aspen Pharmacare Holdings Limited’s price range in the past 12 months?
Aspen Pharmacare Holdings Limited lowest stock price was $5.10 and its highest was $10.18 in the past 12 months.
What is Aspen Pharmacare Holdings Limited’s market cap?
Aspen Pharmacare Holdings Limited’s market cap is $4.32B.
When is Aspen Pharmacare Holdings Limited’s upcoming earnings report date?
Aspen Pharmacare Holdings Limited’s upcoming earnings report date is Sep 02, 2026 which is in 58 days.
How were Aspen Pharmacare Holdings Limited’s earnings last quarter?
Aspen Pharmacare Holdings Limited released its earnings results on Mar 03, 2026. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of N/A by $0.19.
Is Aspen Pharmacare Holdings Limited overvalued?
According to Wall Street analysts Aspen Pharmacare Holdings Limited’s price is currently Overvalued.
Does Aspen Pharmacare Holdings Limited pay dividends?
Aspen Pharmacare Holdings Limited pays a Notavailable dividend of $0.122 which represents an annual dividend yield of 1.52%. See more information on Aspen Pharmacare Holdings Limited dividends here
What is Aspen Pharmacare Holdings Limited’s EPS estimate?
Aspen Pharmacare Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aspen Pharmacare Holdings Limited have?
Aspen Pharmacare Holdings Limited has 446,252,320 shares outstanding.
What happened to Aspen Pharmacare Holdings Limited’s price movement after its last earnings report?
Aspen Pharmacare Holdings Limited reported an EPS of $0.19 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.195%.
Which hedge fund is a major shareholder of Aspen Pharmacare Holdings Limited?
Currently, no hedge funds are holding shares in APNHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aspen Pharmacare Holdings Limited
Operating worldwide, Aspen Pharmacare Holdings Limited, together with its subsidiaries, focuses on the development, production, and global distribution of specialized and branded pharmaceutical products. The company's business activities are structured into two main divisions: Commercial Pharmaceuticals and Manufacturing. Under its Anaesthetics portfolio, Aspen offers diverse products such as general anesthetics, muscle relaxants, and topical agents. Its Thrombosis brand is dedicated to a variety of injectable anticoagulants, with an emphasis on low molecular weight heparins, Xa inhibitors, and heparin derivatives. Additionally, Aspen provides a range of branded consumer, prescription, and over-the-counter medications through regional brands. These include Circadin (for sleep management), Foxair (for respiratory conditions), Maltofer (an iron supplement), Mybulen (a painkiller), and Zyloric (which controls uric acid production). Beyond its proprietary offerings, the company also manufactures and supplies active pharmaceutical ingredients (APIs) and finished dosage form products to external clients. Founded in 1850, Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa.
APNHF Company Deck
APNHF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a cautiously optimistic outlook: commercial pharmaceutical operations are performing well with solid revenue and margin expansion, GLP-1 products are delivering rapid market momentum, and the group has materially improved cash generation. Major near-term headwinds stem from a significant manufacturing contract loss and continuing sterile business losses, which depressed H1 EBITDA and HEPS. The planned APAC divestment (expected net proceeds >ZAR 25 billion) and ongoing cost and reshaping actions are positioned to materially reduce debt, unlock value, and fund a recovery—management expects a much stronger second half and recovery to FY27 levels. Overall, positives (strong cash flow, commercial pharma/GLP-1 growth, APAC monetization) outweigh the near-term negatives (manufacturing/steriles impact and H1 earnings decline), supporting a constructive outlook.View all APNHF earnings summariesTechnical Analysis
1 Day
3 Days
1 Week
1 Month
Bristol-Myers Squibb
―
Dr Reddy's Laboratories
―
Pfizer
―
Bausch Health Companies
―
Sanofi
―
Teva Pharmaceutical
―

